6|9|08

Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions


4|2|08

Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis


1|30|08

Radius Announces Launch of RAD1901 Clinical Program
for the Treatment of Hot Flashes


9|17|07

Radius Grants Major Pharmaceutical Company Exclusive
Option to License BA058 for Osteoporosis / MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius


6|8|07

Radius Presents Positive Results from Phase IB Clinical
Trial of BA058 and Preclinical Study of RAD1901 at ENDO 2007


4|2|07

Radius Raises $57.5 Million in Second Private
Financing Round


3|20|07

Radius Begins Phase II Clinical Trial of BA058 for
Osteoporosis


1|2|07

Radius Appoints Nick Harvey Senior Vice President and CFO


8|7|06

Radius Licenses Worldwide Exclusive Rights to Estrogen
Receptor-Beta Agonists


6|29|06

Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs


4|12|06

Radius Appoints Louis O’Dea Senior Vice President and
Chief Medical Officer


12|13|05

Radius Announces Licensing Agreement for Ipsen
Osteoporosis Proprietary Molecule BA058 / PTHrP Analog in Phase I Clinical Trials


11|12|04

Nuvios* Names Dr. Christopher Glass to Scientific
Advisory Board


10|4|04

Nuvios* Names C. Richard Lyttle President and CEO



*Name changed to Radius effective December 2005

 

© 2005 Radius Health, Inc.   |   Privacy Policy   |   Home   |   Contact

300 Technology Square, Fifth Floor, Cambridge, MA 02139
Tel: (617) 551-4700  |  Fax: (617) 551-4701